Overview A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A Status: NOT_YET_RECRUITING Trial end date: 2031-01-30 Target enrollment: Participant gender: Summary This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.Phase: PHASE2 Details Lead Sponsor: Hoffmann-La Roche